Product Description
SMP-100 is a novel serotonin receptor 3 (5-HT3) partial agonist which has been designed to be a safe and effective therapy for irritable bowel syndrome (IBS) patients. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04296799)
Mechanisms of Action: 5-HT3 Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Chengdu SciMount Pharmatech
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Irritable Bowel Syndrome|Serotonin Syndrome|Diarrhea|Evans Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ChiCTR2300073608 | N/A |
/Completed |
Healthy Volunteers |
2023-03-07 |
2023-07-17 |
Treatments |
|
| CTR20221090 | P1 |
Completed |
Irritable Bowel Syndrome |
2022-10-21 |
2025-04-29 |
Patient Enrollment|Treatments |
|
| SciMount | P1 |
Completed |
Serotonin Syndrome|Evans Syndrome|Diarrhea|Irritable Bowel Syndrome |
2021-11-30 |
12% |
2022-03-12 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date |
| ChengduSciMount | P1 |
Completed |
Irritable Bowel Syndrome|Serotonin Syndrome |
2021-07-26 |
2% |
2022-03-12 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/01/2024 |
PubMed |
Structural basis for partial agonism in 5-HT3A receptors. |
|
04/01/2020 |
PubMed |
CSTI-300 (SMP-100); a Novel 5-HT(3) Receptor Partial Agonist with Potential to Treat Patients with Irritable Bowel Syndrome or Carcinoid Syndrome. |